<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="for New Enemy: Drug Repurposing for Treatment of Newly Emerging" exact="Viral" post="Diseases http://orcid.org/0000-0002-8297-0814GuoDeyinguodeyin@mail.sysu.edu.cn[], grid.12981.330000 0001 2360 039XThe Centre for Infection"/>
 <result pre="New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral" exact="Diseases" post="http://orcid.org/0000-0002-8297-0814GuoDeyinguodeyin@mail.sysu.edu.cn[], grid.12981.330000 0001 2360 039XThe Centre for Infection and"/>
 <result pre="Emerging Viral Diseases http://orcid.org/0000-0002-8297-0814GuoDeyinguodeyin@mail.sysu.edu.cn[], grid.12981.330000 0001 2360 039XThe Centre for" exact="Infection" post="and Immunity Studies, School of Medicine, Sun Yat-sen University,"/>
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="declaration of COVID-19 as a global pandemic. Emerging and re-emerging" exact="viral" post="diseases are a public health concern for the whole"/>
 <result pre="In last decades, numerous major outbreaks of emerging and re-emerging" exact="viral" post="diseases with gross public concern were recorded in different"/>
 <result pre="century, can cause severe diseases with high fatality and morbidity." exact="Severe" post="acute respiratory syndrome (SARS) coronavirus (SARS-CoV) emerged in November"/>
 <result pre="can cause severe diseases with high fatality and morbidity. Severe" exact="acute" post="respiratory syndrome (SARS) coronavirus (SARS-CoV) emerged in November 2002"/>
 <result pre="cause severe diseases with high fatality and morbidity. Severe acute" exact="respiratory" post="syndrome (SARS) coronavirus (SARS-CoV) emerged in November 2002 in"/>
 <result pre="severe diseases with high fatality and morbidity. Severe acute respiratory" exact="syndrome" post="(SARS) coronavirus (SARS-CoV) emerged in November 2002 in Guangdong,"/>
 <result pre="November 2002 in Guangdong, China and caused globally 8098 human" exact="infections" post="with 774 deaths (9.6%), and the Middle East respiratory"/>
 <result pre="human infections with 774 deaths (9.6%), and the Middle East" exact="respiratory" post="syndrome (MERS) coronavirus (MERS-CoV) emerged in 2012 in Saudi"/>
 <result pre="infections with 774 deaths (9.6%), and the Middle East respiratory" exact="syndrome" post="(MERS) coronavirus (MERS-CoV) emerged in 2012 in Saudi Arabia"/>
 <result pre="(MERS-CoV) emerged in 2012 in Saudi Arabia and caused 2494" exact="infections" post="with 858 associated deaths (34.4%) as of November 2019"/>
 <result pre="b). In December 2019, a dozen of patients with unusual" exact="pneumonia" post="were hospitalized in Wuhan in central China, and the"/>
 <result pre="As of January 29, 2020, 7736 confirmed cases of 2019-nCoV" exact="infection" post="with 170 deaths were reported in China, and additional"/>
 <result pre="an urgent need for antiviral treatment in fighting the emerging" exact="viral" post="diseases. However, the development of antiviral drugs is time-"/>
 <result pre="resource-consuming, and thus repurposing of existing drugs to treat emerging" exact="viral" post="diseases represents one of efficient strategies for drug development."/>
 <result pre="against a clinical isolate of 2019-nCoV in a cell culture" exact="infection" post="model (Wang et al.2020). The authors found that two"/>
 <result pre="SI &amp;gt; 88.50) and RDV (EC50 = 0.77 μmol/L; CC50 &amp;gt; 100 μmol/L; SI &amp;gt; 129.87) potently blocked" exact="virus infection" post="at low-micromolar concentration and showed high selectivity index (SI)."/>
 <result pre="and RDV (EC50 = 0.77 μmol/L; CC50 &amp;gt; 100 μmol/L; SI &amp;gt; 129.87) potently blocked virus" exact="infection" post="at low-micromolar concentration and showed high selectivity index (SI)."/>
 <result pre="analogue prodrug and can be incorporated into nascent chains of" exact="viral" post="RNA, resulting in pre-mature termination of RNA synthesis. RDV"/>
 <result pre="Ebola virus (EBOV), Marburg virus, Nipah virus, Hendra virus, and" exact="respiratory" post="syncytial virus in cell culture and mouse infection models"/>
 <result pre="virus, and respiratory syncytial virus in cell culture and mouse" exact="infection" post="models (Warren et al.2016; Sheahan et al.2017; Lo et"/>
 <result pre="identified as a potent inhibitor against 2019-nCoV in cell culture" exact="infection" post="model (Wang et al.2020). CQ, a weak base 4-aminoquinolone"/>
 <result pre="properties and has been approved for the clinical treatment of" exact="autoimmune" post="diseases such as lupus erythematosus and rheumatoid arthritis (Rainsford"/>
 <result pre="approved for the clinical treatment of autoimmune diseases such as" exact="lupus erythematosus" post="and rheumatoid arthritis (Rainsford et al.2015). Recently, CQ has"/>
 <result pre="clinical treatment of autoimmune diseases such as lupus erythematosus and" exact="rheumatoid arthritis" post="(Rainsford et al.2015). Recently, CQ has been proven to"/>
 <result pre="treatment of autoimmune diseases such as lupus erythematosus and rheumatoid" exact="arthritis" post="(Rainsford et al.2015). Recently, CQ has been proven to"/>
 <result pre="including SARS-CoV, MERS-CoV, EBOV, influenza A virus, Chikungunya virus, human" exact="immunodeficiency" post="virus, dengue virus, West Nile virus, Crimean Congo hemorrhagic"/>
 <result pre="virus, human immunodeficiency virus, dengue virus, West Nile virus, Crimean" exact="Congo hemorrhagic fever" post="virus, and hepatitis A virus (García-Serradilla et al.2019). It"/>
 <result pre="virus, West Nile virus, Crimean Congo hemorrhagic fever virus, and" exact="hepatitis" post="A virus (García-Serradilla et al.2019). It is not surprising"/>
 <result pre="al.2019). It is not surprising that CQ can suppress the" exact="infection" post="of a diverse group of viruses. CQ can efficiently"/>
 <result pre="endocytic organelles at some stages of their replication, such as" exact="viral" post="uncoating and cellular entry via membrane fusion. CQ is"/>
 <result pre="fusion. CQ is also able to impair the maturation of" exact="viral" post="proteins and post-translational modification viral receptors like ACE2 for"/>
 <result pre="to impair the maturation of viral proteins and post-translational modification" exact="viral" post="receptors like ACE2 for SARS-CoV by inhibition of pH-dependent"/>
 <result pre="2019-nCoV is currently spreading rapidly in China and causing severe" exact="respiratory" post="diseases and deaths of many patients. As CQ is"/>
 <result pre="As CQ is the first-line drug for the treatment of" exact="malaria" post="and other illnesses with a proven safe record for"/>
 <result pre="be applied and evaluated immediately in the clinical treatment of" exact="acute" post="2019-nCoV infections. For benefits of 2019-nCoV patients, it is"/>
 <result pre="All the repurposed uses of CQ in the treatment of" exact="viral" post="diseases should comply with the regulations of the administrative"/>
 <result pre="epilepsy, and psoriasis. Therefore, when used in the control of" exact="viral" post="diseases, contraindication of CQ should be taken into account"/>
 <result pre="drugs can be repurposed to the antiviral treatment of emerging" exact="viral" post="diseases that do have other effective antiviral treatment. Acknowledgements"/>
 <result pre="and pharmacological properties of hydroxychloroquine and chloroquine in treatment of" exact="systemic" post="lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology20152323126910.1007/s10787-015-0239-y26246395 SavarinoABoelaertJRCassoneAMajoriGCaudaRobertoEffects of"/>
 <result pre="pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic" exact="lupus erythematosus," post="rheumatoid arthritis and related diseasesInflammopharmacology20152323126910.1007/s10787-015-0239-y26246395 SavarinoABoelaertJRCassoneAMajoriGCaudaRobertoEffects of chloroquine on"/>
 <result pre="of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus," exact="rheumatoid arthritis" post="and related diseasesInflammopharmacology20152323126910.1007/s10787-015-0239-y26246395 SavarinoABoelaertJRCassoneAMajoriGCaudaRobertoEffects of chloroquine on viral infections:"/>
 <result pre="hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid" exact="arthritis" post="and related diseasesInflammopharmacology20152323126910.1007/s10787-015-0239-y26246395 SavarinoABoelaertJRCassoneAMajoriGCaudaRobertoEffects of chloroquine on viral infections:"/>
 <result pre="erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology20152323126910.1007/s10787-015-0239-y26246395 SavarinoABoelaertJRCassoneAMajoriGCaudaRobertoEffects of chloroquine on" exact="viral" post="infections: an old drug against today's diseasesLancet Infect Dis2003372272710.1016/S1473-3099(03)00806-514592603"/>
 <result pre="and Research Team (2020) A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med202010.1056/NEJMoa200101731978945"/>
</results>
